Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 27, 2025
Digital Utilities Ventures Secures $3.4M Contract to Deploy Easy FEN™ Sustainable Agriculture Units in Africa
GlobeNewswire
·
March 27, 2025
Key Highlights: Sustainable Agriculture Solution for Africa Digital Utilities Ventures (DUTV) has secured a $3.4 million contract to deploy its patent pending Easy FEN™ modular units in Northern Africa. These advanced systems will convert 35,000 tons of …
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
GlobeNewswire
·
March 27, 2025
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions …
Alzheimer's Data Challenge Names Winners for Innovative Biomarker Research Competition
GlobeNewswire
·
March 27, 2025
WASHINGTON, March 27, 2025 (GLOBE NEWSWIRE) -- International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the …
Prime Biome: Best Probiotic Supplement? Prime Biome Redefines the Skin-Gut Cell Turnover Approach
GlobeNewswire
·
March 27, 2025
ST. PETERSBURG, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Prime Biome emerges as a science-backed breakthrough in a market overflowing with superficial solutions and quick fixes, delivering targeted support for premature aging, digestive discomfort, and …
Premier Health Announces CEO Departure
GlobeNewswire
·
March 27, 2025
MONTRÉAL, March 27, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces that Martin Legault has resigned from his role as President and Chief Executive Officer of the …
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
GlobeNewswire
·
March 27, 2025
SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an update on its strategic and …
FibroBiologics Announces 2025 Annual Meeting of Stockholders
GlobeNewswire
·
March 27, 2025
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System
GlobeNewswire
·
March 27, 2025
The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster CMI Hospital in Bengaluru, India covering a distance over 2,000 km. The SSi Mantra, India’s first CDSCO*-approved surgical …
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
GlobeNewswire
·
March 27, 2025
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in …
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
GlobeNewswire
·
March 27, 2025
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer …
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
GlobeNewswire
·
March 27, 2025
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial …
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
GlobeNewswire
·
March 27, 2025
Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative …
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with …
Organovo Provides Business Update
GlobeNewswire
·
March 27, 2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a …
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
GlobeNewswire
·
March 27, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial …
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
·
March 27, 2025
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
GlobeNewswire
·
March 27, 2025
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American …
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 27, 2025
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven …
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well- …
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 27, 2025
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis …